/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management
Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management

Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management

Research To Practice | Oncology Videos · Oct 8, 2026

Oncology experts analyze frontline and relapsed CLL advances, including time-limited doublets, pirtobrutinib, and emerging BTK degraders.

Minimal Residual Disease Testing Offers No Clinical Value for Continuous BTK Inhibitors

Testing for undetectable MRD is crucial for guiding time-limited venetoclax regimens but not continuous BTK inhibitor therapy. Continuous covalent BTK inhibitors rarely clear MRD despite delivering six to nine years of progression-free survival, making routine MRD assays pointless during ongoing monotherapy.

Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management thumbnail

Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management

Research To Practice | Oncology Videos·a month ago

CLL Patients With Mutated IGHV Sustain Remissions After Stopping One-Year BTK Therapy

Stopping BTK inhibitor monotherapy early is typically discouraged, but patients with mutated IGHV can experience prolonged remissions after fixed-duration treatment. In a French study evaluating stopping acalabrutinib after one year, relapses predominantly clustered in unmutated IGHV cases, whereas mutated patients maintained durable disease control.

Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management thumbnail

Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management

Research To Practice | Oncology Videos·a month ago

FISH Testing Fails to Detect Prognostically Critical TP53 Gene Mutations in CLL

Standard FISH panels only identify 17p deletions and miss sequence-level TP53 mutations that carry similar poor prognoses. Clinicians must specifically order next-generation sequencing alongside stimulated karyotyping, because unstimulated CLL cultures fail to proliferate and can produce false-normal karyotypes.

Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management thumbnail

Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management

Research To Practice | Oncology Videos·a month ago

Adding Obinutuzumab to Acalabrutinib-Venetoclax Spikes Severe Infection Rates Up to 24 Percent

Data from the frontline AMPLIFY trial revealed that adding obinutuzumab to an acalabrutinib and venetoclax doublet doubled grade 3 or higher infections from 10-12% to 24%. While the triplet drove higher undetectable MRD rates, the heightened risk of neutropenia and severe infections argues against its use in older, comorbid patients.

Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management thumbnail

Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management

Research To Practice | Oncology Videos·a month ago

Delayed Obinutuzumab Addition Lowers Toxicity in Triplet Therapy for High-Burden CLL

Initiating acalabrutinib and venetoclax upfront while delaying obinutuzumab effectively debulks tumor load before antibody exposure. This delayed-layering strategy significantly cuts infusion reactions, myelosuppression, and severe infection risk while preserving the deep responses necessary for complex or autoimmune manifestations.

Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management thumbnail

Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management

Research To Practice | Oncology Videos·a month ago

Prior Covalent BTK Inhibitor Exposure Shortens Subsequent Venetoclax Progression-Free Survival

In relapsed CLL, venetoclax-rituximab yields a median progression-free survival of under 40 months following covalent BTK inhibitor failure, compared to 54 months in historical chemoimmunotherapy trials. Intensifying therapy with a pirtobrutinib triplet (PVR) cuts progression risk by nearly half in this aggressive post-covalent BTKI population.

Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management thumbnail

Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management

Research To Practice | Oncology Videos·a month ago

Continuous Frontline BTK Degraders Risk Selecting Pan-Resistant A428D Mutations

Although BTK degraders show exceptional activity in heavily pretreated CLL, using them as continuous frontline monotherapy raises serious sequencing concerns. Early mechanistic data reveal the A428D mutation can emerge, which confers broad cross-resistance to covalent, non-covalent, and degradation-based BTK-targeting therapies.

Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management thumbnail

Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management

Research To Practice | Oncology Videos·a month ago